Beacon Dermatology

Calgary, Alberta T3E 0B2

3 studies enrolling now · 16 studies all time

What they study most

Atopic, Atopic Dermatitis, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic, Hidradenitis Suppurativa, Moderate Plaque Psoriasis, Plaque Psoriasis, Prurigo

Studies at this site

• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) — Recruiting now
• A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — Recruiting now
• A Study of Zasocitinib in Adults With Hidradenitis Suppurativa — Recruiting now
• A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa — Running, not enrolling
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Stopped early
• A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) — Completed
• Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis — Completed
• Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis — Completed
• A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 — Completed
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — Completed
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) — Completed
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Running, not enrolling
• A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Completed
• A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis — Completed
• Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis — Completed
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis — Stopped early